|
Calling our Risk Assessment Experts
|
|
40
|
716
|
July 7, 2025
|
|
CMO Nitrosamine Risk Assessment
|
|
7
|
323
|
June 27, 2025
|
|
How to decide if one anticancer drug is for advanced cancer?
|
|
12
|
540
|
June 13, 2025
|
|
📖 Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines-Pub
|
|
2
|
469
|
May 27, 2025
|
|
🇲🇽 Free Lhasa México Symposia: Shaping the Future of Pharma & Regulation 🇲🇽
|
|
0
|
100
|
May 13, 2025
|
|
Total Nitrosamine Analyzer
|
|
3
|
217
|
May 12, 2025
|
|
Health Canada: Nitrosamine impurities Update July 26, 2024
|
|
16
|
1529
|
May 9, 2025
|
|
Nitrosourea, aromatic n-nitroso copmounds
|
|
2
|
200
|
May 2, 2025
|
|
Risk mitigation based on DP specifications
|
|
10
|
608
|
April 7, 2025
|
|
:brazil: Lhasa Brazil Symposium: Aligning Pharma & Regulatory Standards Globally :brazil:
|
|
0
|
130
|
April 3, 2025
|
|
Dr. Andrew Teasdale on the recent updates on Nitrosamine Impurities - Virtual Workshop
|
|
1
|
625
|
March 15, 2025
|
|
NDSRI in finishe products
|
|
2
|
321
|
March 13, 2025
|
|
DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene
|
|
0
|
124
|
March 6, 2025
|
|
Impact of Antioxidant Excipients on N-nitrosamine Formation and Bioequivalence in Metformin Formulations - Pub
|
|
3
|
609
|
February 11, 2025
|
|
FREE Lhasa Webinar | Nitrosaminas en el horizonte: ¿Está preparado? 🇲🇽
|
|
1
|
251
|
January 22, 2025
|
|
Exploration for Chemical Filter Cartridges that Can Reduce Nitrogen Oxides, a Common Factor in the Formation of Nitrosamines
|
|
0
|
223
|
December 15, 2024
|
|
活性炭成为亚硝酸根来源的风险如何控制？
|
|
3
|
267
|
November 16, 2024
|
|
4-(nitroso(vinyl)amino)butanoic acid from Kollidon?
|
|
7
|
408
|
August 29, 2024
|
|
DMF in API, specification limit in formulation
|
|
5
|
796
|
August 26, 2024
|
|
Control limit of Nitrosamines and N-nitroso compounds
|
|
2
|
481
|
July 8, 2024
|
|
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes -Pub
|
|
0
|
208
|
June 13, 2024
|
|
🇰🇷 Case study on the Occurrence of Impurities in Pharmaceuticals (Focusing on NDMA Cases)
|
|
0
|
356
|
May 31, 2024
|
|
🇪🇺 EDQM - top 10 deficiencies observed in new CEP applications
|
|
0
|
955
|
March 14, 2024
|
|
🇺🇸 FDA CDER Generic Drug Forum (GDF) 2024
|
|
5
|
1400
|
April 14, 2024
|
|
Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub
|
|
0
|
1166
|
June 6, 2023
|
|
Nitrosamine Risk Assessments in Oligonucleotides
|
|
2
|
679
|
August 10, 2023
|